Basilea Pharmaceutica Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
200
- Stock Symbol
-
BSLN
- Investments
-
4
- Share Price
-
$86.95
- (As of Friday Closing)
Basilea Pharmaceutica General Information
Description
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
Contact Information
Website
www.basilea.comCorporate Office
- Hegenheimermattweg 167b
- 4123 Allschwil
- Switzerland
Corporate Office
- Hegenheimermattweg 167b
- 4123 Allschwil
- Switzerland
Basilea Pharmaceutica Stock Performance
As of 13-Nov-2026, Basilea Pharmaceutica’s stock price is $86.95. Its current market cap is $1.08B with 12.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $86.95 | $86.02 | $57.79 - $91.57 | $1.08B | 12.4M | 44.5K | $5.37 |
Basilea Pharmaceutica Financials Summary
As of 30-Jun-2026, Basilea Pharmaceutica has a trailing 12-month revenue of $312M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 730,724 | 810,540 | 610,544 | 598,590 |
| Revenue | 311,756 | 279,602 | 236,843 | 175,359 |
| EBITDA | 78,158 | 59,891 | 73,730 | 23,973 |
| Net Income | 66,006 | 48,417 | 88,123 | 11,626 |
| Total Assets | 368,916 | 356,095 | 285,285 | 206,311 |
| Total Debt | 103,288 | 112,659 | 123,594 | 153,113 |
Basilea Pharmaceutica Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Basilea Pharmaceutica Comparisons
Industry
Financing
Details
Basilea Pharmaceutica Competitors (18)
One of Basilea Pharmaceutica’s 18 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| CSL | Corporation | Melbourne, Australia | ||||
| AstraZeneca | Formerly PE-Backed | Cambridge, United Kingdom | ||||
| Teva Pharmaceutical Industries | Corporation | Tel Aviv, Israel | ||||
| Novartis | Corporation | Basel, Switzerland |
Basilea Pharmaceutica Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Basilea Pharmaceutica Patents
Basilea Pharmaceutica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2017093157-A1 | Piperidine, pyrrolidine and 2-oxo-1,3-oxazinane derivatives as inhibitors of bacterial efflux-pumps for the treatment of microbial infections | Inactive | 30-Nov-2015 | ||
| WO-2017068182-A1 | Use of eb1 as a biomarker of drug response | Inactive | 22-Oct-2015 | ||
| WO-2017042099-A1 | Efflux-pump inhibitors and therapeutic uses thereof | Inactive | 09-Sep-2015 | ||
| WO-2016198691-A1 | Efflux-pump inhibitors and therapeutic uses thereof | Inactive | 11-Jun-2015 | ||
| WO-2016128465-A1 | Substituted mono- and polyazanaphthalene derivatives and their use | Inactive | 11-Feb-2015 | C07D217/04 |
Basilea Pharmaceutica Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Basilea Pharmaceutica Investments (4)
Basilea Pharmaceutica’s most recent deal was a Corporate Asset Purchase with Venatorx (Ceftibuten-Ledaborbactam Etzadroxil Antibiotic Drug) for . The deal was made on 14-Aug-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Venatorx (Ceftibuten-Ledaborbactam Etzadroxil Antibiotic Drug) | 14-Aug-2025 | Corporate Asset Purchase | Pharmaceuticals | ||
| Spexis (Preclinical Antibiotic Program) | 15-Jan-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Gravitas Therapeutics (BAL2062) | 22-Dec-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Crossfire Oncology (BAL0891) | 01-Jan-2018 | Corporate Asset Purchase | Drug Discovery |
Basilea Pharmaceutica ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.08 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Basilea Pharmaceutica Exits (1)
Basilea Pharmaceutica’s most recent exit was on 01-Jan-2018 from Crossfire Oncology (BAL0891). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Crossfire Oncology (BAL0891) | 01-Jan-2018 | Completed |
|
Basilea Pharmaceutica FAQs
-
When was Basilea Pharmaceutica founded?
Basilea Pharmaceutica was founded in 2000.
-
Where is Basilea Pharmaceutica headquartered?
Basilea Pharmaceutica is headquartered in Allschwil, Switzerland.
-
What is the size of Basilea Pharmaceutica?
Basilea Pharmaceutica has 200 total employees.
-
What industry is Basilea Pharmaceutica in?
Basilea Pharmaceutica’s primary industry is Drug Discovery.
-
Is Basilea Pharmaceutica a private or public company?
Basilea Pharmaceutica is a Public company.
-
What is Basilea Pharmaceutica’s stock symbol?
The ticker symbol for Basilea Pharmaceutica is BSLN.
-
What is the current stock price of Basilea Pharmaceutica?
As of 13-Nov-2026 the stock price of Basilea Pharmaceutica is $86.95.
-
What is the current market cap of Basilea Pharmaceutica?
The current market capitalization of Basilea Pharmaceutica is $1.08B.
-
What is Basilea Pharmaceutica’s current revenue?
The trailing twelve month revenue for Basilea Pharmaceutica is $312M.
-
Who are Basilea Pharmaceutica’s competitors?
Astellas Pharma, CSL, AstraZeneca, Teva Pharmaceutical Industries, and Novartis are some of the 18 competitors of Basilea Pharmaceutica.
-
What is Basilea Pharmaceutica’s annual earnings per share (EPS)?
Basilea Pharmaceutica’s EPS for 12 months was $5.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
